Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS

Abstract We have retrospectively compared survivals between acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received either a clofarabine/busulfan (CloB2A2) or a fludarabine/busulfan (FB2A2) RIC regimen for allogeneic stem cell transplantation. Between 2009 and 2014, 355 all...

Full description

Bibliographic Details
Main Authors: Patrice Chevallier, Myriam Labopin, Regis Peffault deLa Tour, Bruno Lioure, Claude‐Eric Bulabois, Anne Huynh, Didier Blaise, Pascal Turlure, Etienne Daguindau, Natacha Maillard, Ibrahim Yakoub‐Agha, Gaelle Guillerm, Jeremy Delage, Nathalie Contentin, Jacques‐Olivier Bay, Florence Beckerich, Jean‐Henri Bourhis, Marie Detrait, Stéphane Vigouroux, Sylvie François, Faezeh Legrand, Thierry Guillaume, Mohamad Mohty, the SFGM‐TC
Format: Article
Language:English
Published: Wiley 2016-11-01
Series:Cancer Medicine
Subjects:
Acute myeloid leukemia
allogeneic stem cell transplantation
clofarabine
fludarabine
myelodysplastic syndrome
reduced‐toxicity conditioning regimen
Online Access:https://doi.org/10.1002/cam4.880

Internet

https://doi.org/10.1002/cam4.880

Similar Items